News

2 Years of Vidofludimus Calcium Thwarts Disability Progression: Data

Most adults with relapsing-remitting multiple sclerosis (RRMS) who received Immunic Therapeutics‘ investigational therapy vidofludimus calcium have had no confirmed disability progression after two years of treatment. That’s according to new interim data from the open-label extension portion of the EMPhASIS trial, which has been running for nearly…

Fountain Health Now Fully Covers Cost of Combinostics’ Tests

Insurer Fountain Health now will fully cover Combinostics’ artificial intelligence (AI)-based tools to support the early detection, differential diagnosis, and prediction of progression in patients with neurodegenerative disorders such as multiple sclerosis (MS). The decision to cover the company’s cloud-based AI platforms, cMRI and cDSI,…

How Stem Cell Transplant Can ‘Reset’ Immune System in MS: Study

Following an autologous hematopoietic stem cell transplant (aHSCT) in people with multiple sclerosis (MS), the population of “naïve” T-cells — components of the immune system that enable the body to fight off new, unrecognized infections — is completely renewed but some memory T-cells, which are responsible for rapid responses…

Treatments Seen to Account for Largest Part of MS Financial Burden

Medications account for the majority of costs related to managing multiple sclerosis (MS) in Italy, and secondary-progressive MS (SPMS) is associated with higher treatment and healthcare costs than those for relapsing-remitting multiple sclerosis (RRMS), a study looking at real-world data reported. “A bigger healthcare resource consumption was retrieved for…

Rituximab Doses for MS Might Be Best Timed By Measuring B-cells

Timing doses of rituximab by measuring B-cell counts is a more tailored approach to treatment, and it effectively reduces relapses and disability progression in multiple sclerosis (MS), according to a small study in patients with active disease. This tailored approach allowed patients to receive less frequent doses if their B-cell counts…

Dietary Changes Can Help Ease Fatigue, Improve Quality of Life

Dietary interventions may help ease fatigue and improve quality of life in people with multiple sclerosis (MS), although it doesn’t seem to impact disability progression, according to a new analysis. Researchers emphasized that it’s difficult to draw solid conclusions about the impact of diet in MS because there haven’t…

Expert Voices: What Causes Multiple Sclerosis?

In this installment of our “Expert Voices” series, Multiple Sclerosis News Today asked Brandon Beaber, MD, to answer some of your questions about research into the causes of multiple sclerosis (MS). Beaber is a board-certified neurologist and MS specialist. He makes videos about MS on YouTube and…

Saint Louis University Opens Neuroscience Research Institute

With an overarching goal of improving patients’ health and life quality, Saint Louis University (SLU) has opened an institute for neuroscience researchers working in a variety of fields to study disorders of the central nervous system, including multiple sclerosis (MS). The Institute for Translational Neuroscience (ITN), an outgrowth of the…

NMSS Grant Supports Work Into Epstein-Barr Virus as MS Trigger

A National Multiple Sclerosis Society grant is supporting an Australian-led research team aiming to better understand how the Epstein-Barr virus (EBV) may be acting as a trigger for multiple sclerosis (MS). The funding will particularly be used to understand what molecules are being targeted by lymphocytes, immune cells that…

#ECTRIMS2022 – Vumerity Lowers RRMS Activity Over 2 Years

Up to two years of Vumerity (diroximel fumarate) treatment was generally well-tolerated and led to significant decreases in disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to a final analysis of data from the open-label EVOLVE-MS-1 Phase 3 clinical trial. Indirect comparisons of Vumerity-treated patients against those…